Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach?

European Journal of Cancer

Volumn 45, Issue 13, 2009, Pages 2274-2283

  Brauch, Hiltrud ^a   Jordan, V Craig ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast cancer; CYP2D6; Drug interaction; Poor metaboliser; Tamoxifen pharmacogenomics

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE; TAMOXIFEN; VENLAFAXINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DNA POLYMORPHISM; DRUG EFFICACY; GENOTYPE; HUMAN; METABOLIC ACTIVATION; MONOTHERAPY; PHARMACOGENOMICS; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; TAMOXIFEN;

EID: 68749113944     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.032     Document Type: Article

References (89)

1. Jordan V.C. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2 3 (2003) 205-213
2. Cole M.P., Jones C.T., and Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25 2 (1971) 270-275
3. NATO. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1 8319 (1983) 257-261
4. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320 8 (1989) 479-484
5. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 9354 (2003) 296-300
6. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 22 (2005) 1652-1662
7. Powles T.J., Ashley S., Tidy A., Smith I.E., and Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 4 (2007) 283-290
8. Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304 1 (1981) 16-21
9. Jordan V.C., and Koerner S. Tamoxifen (ICI 46, 474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11 3 (1975) 205-206
10. Jordan V.C., and Allen K.E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16 2 (1980) 239-251
11. Jordan V.C. Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12 6 (1976) 419-424
12. Powles T.J., Hardy J.R., Ashley S.E., et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60 1 (1989) 126-131
13. Jordan V.C. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44 1 (2008) 30-38
14. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 9114 (1998) 1451-1467
15. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
16. Jordan V.C., and Brodie A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 1 (2007) 7-25
17. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
18. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
19. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
20. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
21. Lien E.A., Solheim E., Kvinnsland S., and Ueland P.M. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48 8 (1988) 2304-2308
22. Lien E.A., Solheim E., Lea O.A., Lundgren S., Kvinnsland S., and Ueland P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49 8 (1989) 2175-2183
23. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 23 (2003) 1758-1764
24. Jordan V.C. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72 13 (2007) 829-842
25. Jordan V.C., Collins M.M., Rowsby L., and Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75 2 (1977) 305-316
26. Allen K.E., Clark E.R., and Jordan V.C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 71 1 (1980) 83-91
27. Lim Y.C., Desta Z., Flockhart D.A., and Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55 5 (2005) 471-478
28. Johnson M.D., Zuo H., Lee K.H., et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85 2 (2004) 151-159
29. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 1 (2005) 30-39
30. Lim Y.C., Li L., Desta Z., et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318 2 (2006) 503-512
31. Wu X., Hawse J.R., Subramaniam M., Goetz M.P., Ingle J.N., and Spelsberg T.C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69 5 (2009) 1722-1727
32. Pike A.C., Brzozowski A.M., Walton J., et al. Structural insights into the mode of action of a pure antiestrogen. Structure 9 2 (2001) 145-153
33. Wu Y.L., Yang X., Ren Z., et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18 4 (2005) 413-424
34. Shiau A.K., Barstad D., Loria P.M., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 7 (1998) 927-937
35. Desta Z., Ward B.A., Soukhova N.V., and Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310 3 (2004) 1062-1075
36. Eichelbaum M., Spannbrucker N., and Dengler H.J. Proceedings: N-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch Pharmacol 287 Suppl. (1975) R94
37. Mahgoub A., Idle J.R., Dring L.G., Lancaster R., and Smith R.L. Polymorphic hydroxylation of Debrisoquine in man. Lancet 2 8038 (1977) 584-586
38. Griese E.U., Zanger U.M., Brudermanns U., et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8 1 (1998) 15-26
39. Raimundo S., Toscano C., Klein K., et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76 2 (2004) 128-138
40. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60 2 (1997) 284-295
41. Sistonen J., Sajantila A., Lao O., Corander J., Barbujani G., and Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17 2 (2007) 93-101
42. Marez D., Legrand M., Sabbagh N., et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7 3 (1997) 193-202
43. Zanger U.M., Turpeinen M., Klein K., and Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392 6 (2008) 1093-1108
44. Raimundo S., Fischer J., Eichelbaum M., Griese E.U., Schwab M., and Zanger U.M. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10 7 (2000) 577-581
45. Toscano C., Klein K., Blievernicht J., et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 16 10 (2006) 755-766
46. Zanger U.M., Fischer J., Raimundo S., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11 7 (2001) 573-585
47. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369 1 (2004) 23-37
48. Dahl M.L., Johansson I., Bertilsson L., Ingelman-Sundberg M., and Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274 1 (1995) 516-520
49. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjoqvist F., and Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90 24 (1993) 11825-11829
50. Bertilsson L., Dahl M.L., Sjoqvist F., et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341 8836 (1993) 63
51. Dalen P., Dahl M.L., Bernal Ruiz M.L., Nordin J., and Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63 4 (1998) 444-452
52. Lovlie R., Daly A.K., Matre G.E., Molven A., and Steen V.M. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics 11 1 (2001) 45-55
53. Aklillu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., and Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278 1 (1996) 441-446
54. McLellan R.A., Oscarson M., Seidegard J., Evans D.A., and Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7 3 (1997) 187-191
55. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5 1 (2005) 6-13
56. Borges S., Desta Z., Li L., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80 1 (2006) 61-74
57. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 36 (2005) 9312-9318
58. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 1 (2007) 113-121
59. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25 33 (2007) 5187-5193
60. Lim H.S., Ju L.H., Seok L.K., Sook L.E., Jang I.J., and Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25 25 (2007) 3837-3845
61. Xu Y., Sun Y., Yao L., et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19 8 (2008) 1423-1429
62. Kiyotani K., Mushiroda T., Sasa M., et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99 5 (2008) 995-999
63. Nowell S.A., Ahn J., Rae J.M., et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91 3 (2005) 249-258
64. Wegman P., Vainikka L., Stal O., et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7 3 (2005) R284-R290
65. Wegman P., Elingarami S., Carstensen J., Stal O., Nordenskjold B., and Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9 1 (2007) R7
66. Bonanni B., Macis D., Maisonneuve P., et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24 22 (2006) 3708-3709
67. Newman W.G., Hadfield K.D., Latif A., et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 14 18 (2008) 5913-5918
68. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 9122 (1998) 98-101
69. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
70. Demissie S., Silliman R.A., and Lash T.L. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19 2 (2001) 322-328
71. Fink A.K., Gurwitz J., Rakowski W., Guadagnoli E., and Silliman R.A. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22 16 (2004) 3309-3315
72. Lash T.L., Fox M.P., Westrup J.L., Fink A.K., and Silliman R.A. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99 2 (2006) 215-220
73. McCowan C., Shearer J., Donnan P.T., et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99 11 (2008) 1763-1768
74. Partridge A.H., Wang P.S., Winer E.P., and Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21 4 (2003) 602-606
75. Barron T.I., Connolly R., Bennett K., Feely J., and Kennedy M.J. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109 5 (2007) 832-839
76. Fallowfield L. Acceptance of adjuvant therapy and quality of life issues. Breast 14 6 (2005) 612-616
77. Owusu C., Buist D.S., Field T.S., et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26 4 (2008) 549-555
78. Mortimer J.E., Flatt S.W., Parker B.A., et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108 3 (2008) 421-426
79. Gjerde J., Hauglid M., Breilid H., et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19 1 (2008) 56-61
80. Decensi A., Gandini S., Serrano D., et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 25 27 (2007) 4201-4209
81. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356 9247 (2000) 2059-2063
82. Loprinzi C.L., Sloan J.A., Perez E.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20 6 (2002) 1578-1583
83. Stearns V., Beebe K.L., Iyengar M., and Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289 21 (2003) 2827-2834
84. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., and Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34 3 (1992) 262-265
85. Jeppesen U., Gram L.F., Vistisen K., Loft S., Poulsen H.E., and Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51 1 (1996) 73-78
86. Hickey M., Davis S.R., and Sturdee D.W. Treatment of menopausal symptoms: what shall we do now?. Lancet 366 9483 (2005) 409-421
87. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 5 (2007) 486-492
88. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., and Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 1 (2008) 45-53
89. Punglia R.S., Burstein H.J., Winer E.P., and Weeks J.C. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 100 9 (2008) 642-648